查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1733155

全球血漿市場規模（按成分、最終用戶、區域範圍和預測）

Global Blood Plasma Market Size By Component (Immunoglobulin, Albumin), By End-User (Hospitals, Clinics), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

等離子市場規模及預測

2024 年等離子市場規模價值為 412.6 億美元，預計到 2032 年將達到 834.4 億美元，2026 年至 2032 年的複合年成長率為 9.2%。

  • 血漿是血球（紅血球、白血球和血小板）被移除後剩下的淡黃色液體。血漿約佔總血液量的 55%，主要由水（約 90%）、蛋白質、電解質、荷爾蒙、營養物質和廢物組成。
  • 血漿是將這些物質運送到全身的重要載體，在維持血壓、酸鹼平衡和整體體內平衡方面發揮著至關重要的作用。
  • 血漿具有多種醫療用途，特別是在輸血醫學和治療方面。血漿對於血友病患者生產凝血因子濃縮物至關重要，也用於製備免疫球蛋白以治療各種免疫力缺乏。
  • 此外，白蛋白和凝血因子等血漿衍生產品對於治療肝病、休克和燒燙傷等病症至關重要。近年來，等離子體也因其在再生醫學中的潛力而受到關注，包括創傷治療和美容治療中的應用。

全球血漿市場動態

影響全球等離子市場的關鍵市場動態是：

關鍵市場促進因素

  • 對血漿衍生療法的需求不斷成長：對血漿衍生療法的需求不斷成長是血漿市場的主要驅動力。血友病和免疫力缺乏等疾病需要這些治療才能有效。根據血漿蛋白治療協會 (PPTA) 的數據，全球血漿衍生療法市場預計將在 2023 年達到 286 億美元，到 2028 年的複合年成長率為 6.8%。
  • 提高捐血意識：提高捐血重要性的認知導致血漿供應增加。公共衛生宣傳活動鼓勵更多人捐血，從而擴大血漿供應。根據血漿蛋白治療協會 (PPTA) 的數據，全球血漿衍生療法市場預計將在 2023 年達到 286 億美元，到 2028 年的複合年成長率為 6.8%。
  • 慢性病發病率不斷上升：自體免疫疾病等慢性病的增加推動了對血漿產品的需求。這一趨勢凸顯了血漿在管理複雜健康狀況中的重要作用。根據美國疾病管制與預防中心 (CDC) 的數據，截至 2023 年，美國美國患有自體免疫疾病的比例預計將從 2018 年的 4.5% 上升至 6%。
  • 增加對生物技術的投資：增加對生物技術和研究的投資正在加強血漿衍生產品的開發。加工和配方方面的創新正在帶來更有效的治療方法和更廣泛的用途。根據美國國立衛生研究院（NIH）的報告，2023會計年度與血漿衍生療法相關的研究支出將達到12億美元，比上年度增加15%。
  • 增加對血漿產品的監管支持：增加對血漿產品安全性和有效性的監管支持正在建立市場信心。這種支持性環境鼓勵製造商投資於品質改進和新產品開發。 FDA 報告稱，2023 年核准的血漿衍生療法數量將比 2020 年增加 30%，反映出核准流程更加簡化，人們對這些產品的信心也增強。

主要問題

  • 法規日益增多：有關血漿收集和使用的法規日益增多可能會阻礙市場擴張。遵守嚴格的指導方針會增加製造商和經銷商的複雜性和成本。
  • 對捐贈者安全的日益擔憂：對捐贈者安全和潛在副作用的日益擔憂可能會影響血漿供應。這些擔憂可能會阻止人們捐血並導致供不應求。
  • 社會認知問題日益嚴重：與捐血和血漿產品相關的社會認知問題日益嚴重可能成為市場成長的障礙。錯誤訊息和負面情緒可能會阻礙潛在的捐血和消費者。
  • 來自替代療法的競爭日益激烈：來自替代療法和治療方法的競爭日益激烈，對血漿市場構成了挑戰。新興技術可能提供替代療法並減少對傳統血漿療法的依賴。

主要趨勢

  • 更重視免疫球蛋白療法：更重視免疫球蛋白療法正在改變血漿市場。隨著人們越來越認知到免疫球蛋白治療免疫力缺乏和自體免疫疾病的有效性，其需求也正在飆升。醫療保健提供者擴大採用免疫球蛋白療法，從而增加了對血漿收集和處理的投資。這一趨勢凸顯了血漿衍生產品在現代醫學中的重要角色。
  • 對血漿衍生生技藥品的需求不斷增加：對凝血因子和白蛋白等血漿衍生生技藥品的需求不斷增加，它們對於治療各種疾病至關重要。這一趨勢是由對慢性疾病、外科手術和創傷護理日益成長的需求所推動的。隨著越來越多的患者需要這些救命的療法，製造商正在擴大其產品線以滿足這一需求。對高品質生技藥品的重視正在推動血漿處理技術的創新。
  • 自動血漿採集的採用率不斷提高：自動血漿採集技術的採用率不斷提高，並且正在徹底改變整個產業。自動化提高了血漿採集過程的效率和安全性，從而提高了產量並改善了捐贈者的體驗。這些先進系統的實施將使設施能夠滿足日益成長的等離子產品需求。這種趨勢不僅簡化了業務，而且還透過最大限度地減少採集過程中的不適來幫助吸引更多的捐贈者。

目錄

第1章 全球等離子市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球等離子市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章全球血漿市場：依成分

  • 概述
  • 免疫球蛋白
  • 白蛋白
  • 凝血因子濃縮物
  • 其他

6. 全球等離子市場（依最終用戶）

  • 概述
  • 醫院
  • 診所
  • 實驗室

7. 全球等離子市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他
    • 拉丁美洲
    • 中東

8. 全球等離子市場的競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略

第9章 公司簡介

  • CSL Behring
  • Grifols
  • Baxter International, Inc.
  • Octapharma
  • Shire（現為武田藥品工業株式會社的子公司）
  • Kedrion Biopharma
  • China Biologic Products Holdings, Inc
  • LFB Group, BIoTest AG.

第10章 附錄

  • 相關調查
簡介目錄
Product Code: 32646

Blood Plasma Market Size And Forecast

Blood Plasma Market size was valued at USD 41.26 Billion in 2024 and is projected to reach USD 83.44 Billion by 2032, growing at a CAGR of 9.2% from 2026 to 2032.

  • Blood plasma is the yellowish, liquid component of blood that remains after the blood cells (red cells, white cells, and platelets) have been removed. Comprising about 55% of total blood volume, plasma is primarily composed of water (around 90%), along with proteins, electrolytes, hormones, nutrients, and waste products.
  • It serves as a crucial medium for transporting these substances throughout the body, playing an essential role in maintaining blood pressure, pH balance, and overall homeostasis.
  • Plasma has numerous medical applications, particularly in transfusion medicine and therapeutic treatments. It is vital for the production of clotting factor concentrates for patients with hemophilia and is also used in the formulation of immunoglobulins to treat various immune deficiencies.
  • Additionally, plasma-derived products, such as albumin and clotting factors, are critical in managing conditions like liver disease, shock, and burns. In recent years, plasma has also gained attention for its potential in regenerative medicine, including applications in wound healing and aesthetic treatments.

Global Blood Plasma Market Dynamics

The key market dynamics that are shaping the global blood plasma market include:

Key Market Drivers

  • Rising Demand for Plasma-Derived Therapies: The rising demand for plasma-derived therapies is significantly driving the blood plasma market. Conditions such as hemophilia and immune deficiencies require these therapies for effective treatment. According to the Plasma Protein Therapeutics Association (PPTA), the global market for plasma-derived therapies reached USD 28.6 Billion in 2023, with a projected CAGR of 6.8% through 2028.
  • Growing Awareness of Blood Donation: Growing awareness of the importance of blood donation is increasing the availability of plasma. Public health campaigns are encouraging more individuals to donate, thereby expanding the plasma supply. According to the Plasma Protein Therapeutics Association (PPTA), the global market for plasma-derived therapies reached USD 28.6 Billion in 2023, with a projected CAGR of 6.8% through 2028.
  • Increasing Incidence of Chronic Diseases: The increasing incidence of chronic diseases, such as autoimmune disorders, is boosting the need for plasma products. This trend emphasizes the essential role of plasma in managing complex health conditions. According to the Centers for Disease Control and Prevention (CDC), as of 2023, an estimated 6% of the U.S. population was living with an autoimmune disease, up from 4.5% in 2018.
  • Rising Investment in Biotechnology: Rising investment in biotechnology and research is enhancing the development of plasma-derived products. Innovations in processing and formulation are leading to more effective therapies and expanded applications. The National Institutes of Health (NIH) reported that funding for research related to plasma-derived therapies reached USD 1.2 Billion in fiscal year 2023, a 15% increase from the previous year.
  • Growing Regulatory Support for Plasma Products: Growing regulatory support for the safety and efficacy of plasma products is fostering market confidence. This supportive environment encourages manufacturers to invest in quality improvements and new product development. The FDA reported a 30% increase in the number of approved plasma-derived therapies in 2023 compared to 2020, reflecting a more streamlined approval process and growing confidence in these products.

Key Challenges:

  • Increasing Regulatory Scrutiny: The increasing regulatory scrutiny surrounding blood plasma collection and use can hinder market expansion. Compliance with stringent guidelines adds complexity and costs for manufacturers and distributors.
  • Rising Concerns over Donor Safety: Rising concerns about donor safety and the potential for adverse effects can affect plasma supply. These apprehensions may discourage individuals from donating, leading to shortages in plasma availability.
  • Growing Public Perception Issues: Growing public perception issues related to blood donation and plasma products can create barriers to market growth. Misinformation or negative sentiments can deter potential donors and consumers alike.
  • Growing Competition from Alternatives: Growing competition from alternative therapies and treatments poses a challenge to the blood plasma market. Emerging technologies may offer substitutes that reduce reliance on traditional plasma-derived therapies.

Key Trends

  • Rising Focus on Immunoglobulin Therapies: The rising focus on immunoglobulin therapies is transforming the blood plasma market. As awareness grows about the effectiveness of these treatments for immune deficiencies and autoimmune diseases, demand is surging. Healthcare providers are increasingly prescribing immunoglobulin therapies, leading to greater investment in plasma collection and processing. This trend highlights the critical role of plasma-derived products in modern medicine.
  • Growing Demand for Plasma-Derived Biologics: There is a growing demand for plasma-derived biologics, including clotting factors and albumin, essential for managing various medical conditions. This trend is fueled by an increasing prevalence of chronic diseases, surgical procedures, and trauma care needs. As more patients require these life-saving therapies, manufacturers are expanding their product lines to meet this demand. The emphasis on high-quality biologics is driving innovation in plasma processing technologies.
  • Increasing Adoption of Automated Plasma Collection: The increasing adoption of automated plasma collection technologies is revolutionizing the industry. Automation improves the efficiency and safety of the collection process, resulting in higher yields and enhanced donor experience. As facilities implement these advanced systems, they can better meet the rising demand for plasma products. This trend not only streamlines operations but also helps attract more donors by minimizing discomfort during the collection process.

Global Blood Plasma Market Regional Analysis

Here is a more detailed regional analysis of the global blood plasma market:

North America

  • North America leads the global blood plasma market, driven by advanced healthcare infrastructure, high awareness of plasma-derived therapies, and a well-established plasma collection network. The United States dominates the region's market share, with its robust regulatory framework and high plasma donation rates.
  • According to the U.S. Food and Drug Administration, there were 943 licensed plasma collection centers in the country as of 2023, demonstrating the significant capacity for plasma collection and processing in the region.
  • The region's dominance is further strengthened by the presence of major plasma fractionation companies and their ongoing investments in expanding production capabilities. Key players like CSL Limited and Grifols S.A. have been actively increasing their plasma collection and fractionation capacities to meet growing demand. In a recent development, Grifols announced in March 2024 the opening of a new plasma fractionation facility in North Carolina, USA, with an annual capacity of processing 6 million liters of plasma, potentially boosting the region's market position.

Asia Pacific

  • The Asia Pacific region is experiencing rapid growth in the Blood Plasma Market, driven by improving healthcare infrastructure, increasing awareness of plasma-derived therapies, and rising prevalence of chronic diseases. Countries like China, India, and Japan are at the forefront of this expansion, with their governments investing heavily in healthcare systems and promoting plasma donation.
  • According to China's National Medical Products Administration, the country's plasma-derived medicinal products market reached 30.8 billion yuan in 2023, highlighting the significant growth potential in the region.
  • The market's growth is further propelled by the rising demand for immunoglobulins and other plasma-derived products for treating various immune deficiencies and rare diseases. Key players in the global blood plasma market are recognizing this potential and expanding their presence in Asia Pacific. In a recent development, Takeda Pharmaceutical Company Limited announced in February 2024 the completion of its new plasma fractionation facility in Guangzhou, China, with an annual production capacity of 1.2 million liters of plasma, aimed at meeting the growing demand for plasma-derived therapies in the region.

Global Blood Plasma Market: Segmentation Analysis

The Global Blood Plasma Market is segmented based on Component, End-User, And Geography.

Blood Plasma Market, By Component

  • Immunoglobulin
  • Albumin
  • Coagulation Factor Concentrates
  • Others

Based on Component, the Global Blood Plasma Market is bifurcated into Immunoglobulin, Albumin, Coagulation Factor Concentrates, and Others. In the blood plasma market, immunoglobulin is the dominant component, primarily due to its critical role in treating various immune deficiencies and autoimmune disorders. Conversely, the albumin segment is rapidly growing, driven by its increasing applications in critical care settings, including surgeries and liver diseases, as well as its use in drug formulation. The rising demand for albumin-based therapies and its versatility in various medical applications are key factors contributing to this segment's expansion.

Blood Plasma Market, By End-User

  • Hospitals
  • Clinics
  • Research Laboratories

Based on End-User, the Global Blood Plasma Market is bifurcated into Hospitals, Clinics, and Research Laboratories. In the blood plasma market, hospitals currently dominate as the primary end-user, driven by the high demand for plasma-derived therapies and transfusions in critical care settings. Meanwhile, the research laboratories segment is experiencing rapid growth, fueled by increasing investments in research related to plasma-derived products and their applications in various medical fields. The expansion of biopharmaceutical research and the development of new therapies utilizing plasma components are key factors contributing to the growth of this segment.

Blood Plasma Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Global Blood Plasma Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the blood plasma market, North America is the dominant region, primarily due to its advanced healthcare infrastructure, high prevalence of plasma-derived therapies, and significant investment in research and development. Conversely, the Asia Pacific region is rapidly growing, driven by increasing healthcare expenditures, rising awareness of plasma therapies, and the expansion of healthcare facilities in countries like China and India. This growth is further supported by a rising incidence of chronic diseases and the demand for innovative treatment options, positioning Asia Pacific as a key area for future market expansion.

Key Players

The "Global Blood Plasma Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are CSL Behring, Grifols, Baxter International, Inc., Octapharma, Shire (now part of Takeda Pharmaceutical Company), Kedrion Biopharma, Bio Products Laboratory, China Biologic Products Holdings, Inc., LFB Group, Biotest AG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Blood Plasma Market Key Developments

  • In September 2023, Grifols announced the expansion of its plasma collection network in North America, aiming to increase access to high-quality plasma for immunotherapy and other treatments.
  • In August 2023, CSL Behring launched a new high-purity immunoglobulin product, enhancing treatment options for patients with immune deficiencies and autoimmune diseases.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD PLASMA MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL BLOOD PLASMA MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL BLOOD PLASMA MARKET, BY Component

  • 5.1 Overview
  • 5.2 Immunoglobulin
  • 5.3 Albumin
  • 5.4 Coagulation Factor Concentrates
  • 5.5 Others

6 GLOBAL BLOOD PLASMA MARKET, BY END-USER

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Clinics
  • 6.4 Research Laboratories

7 GLOBAL BLOOD PLASMA MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East

8 GLOBAL BLOOD PLASMA MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 CSL Behring
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Grifols
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Baxter International, Inc.
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Octapharma
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Shire (now part of Takeda Pharmaceutical Company)
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Kedrion Biopharma
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 China Biologic Products Holdings, Inc
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.9 LFB Group, Biotest AG.
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments

10 Appendix

  • 11.1 Related Research